Parkinson’s disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group: Participants in the intervention group will receive two 500 milligram tablets containing standardized ginger powder daily for twelve weeks. Each tablet contains 500
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age between 50 and 80 years Body Mass Index (BMI) greater than 18.5 Patients willing to participate in the study and able to provide written informed consent Diagnosis of Parkinson’s disease confirmed by a neurologist based on established diagnostic criteria Stable medication regimen for at least one month prior to the beginning of the study
Exclusion criteria
Exclusion criteria: Following specific dietary regimens (such as ketogenic, fasting, etc.) within one month before the start of the study Consumption of ginger-enriched products within one month before the start of the study Presence of hypo- or hyperthyroidism Presence of severe psychosis or other concurrent neurological disorders Cognitive impairment based on the MOCA criteria Mood disorders such as severe depression, bipolar disorder, or severe anxiety (as determined by a neurologist) Known allergy or hypersensitivity to ginger Hoehn and Yahr score equal to 5 Use of cigarettes, nicotine, or alcohol Use of anticoagulant medications Use of anti-inflammatory or immunosuppressive drugs Receiving insulin therapy Use of antioxidant supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Parkinson’s disease severity based on the total score of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale. Timepoint: Assessment of Parkinson’s disease severity at baseline before the start of the intervention and at the end of week twelve after completion of the intervention. Method of measurement: Movement Disorder Society Unified Parkinson’s Disease Rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum level of Superoxide dismutase. Timepoint: Measurement of serum Superoxide dismutase at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum Superoxide dismutase using standard biochemical methods.;Change in serum level of Glutathione peroxidase. Timepoint: Measurement of serum Glutathione peroxidase at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum Glutathione peroxidase using standard biochemical methods.;Change in serum total antioxidant capacity. Timepoint: Measurement of serum total antioxidant capacity at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum total antioxidant capacity using standard biochemical methods.;Change in serum total oxidant status. Timepoint: Measurement of serum total oxidant status at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum total oxidant status using standard biochemical methods.;Change in quality of life in patients with Parkinson’s disease. Timepoint: Assessment of quality of life in patients with Parkinson’s disease at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Parkinson’s disease quality of life questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaziar Ghasemi
Esfahan University of Medical Sciences
Outcome results
None listed